NCT06798376

Different Cycles of Neoadjuvant PD-1 Blockades + Chemotherapy for Advanced Gastric Cancer

The Comparison of Different Cycles of PD-1 Blockades Combined with Chemotherapy As Neoadjuvant Therapy for Patients with Advanced Gastric Cancer

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 300 (estimated)
• Sponsor: Chinese PLA General Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The goal of this observational study is to analyze the impact of different durations of neoadjuvant PD-1 inhibitor combined with chemotherapy on tumor regression and safety in patients with advanced gastric cancer. The main questions it aims to answer are: * Does the duration of neoadjuvant treatment influence tumor regression grading (TRG)? * How does treatment duration affect perioperative safety and clinical outcomes? Participants who have previously undergone neoadjuvant PD-1 inhibitor combined with chemotherapy followed by surgery as part of their routine medical care will have their clinical data retrospectively reviewed and analyzed.

Conditions

• Gastric Adenocarcinoma

Interventions

Type	Name	Description
DRUG	≤4 cycles of neoadjuvant PD-1 Inhibitors combined with chemotherapy	Any PD-1 inhibitors combined with any chemotherapy regimen given before surgery for no more than 4 cycles
DRUG	≥5 cycles of neoadjuvant PD-1 Inhibitors combined with chemotherapy	Any PD-1 inhibitors combined with any chemotherapy regimen given before surgery for no less than 5 cycles
PROCEDURE	Gastrectomy	Any type of surgical procedure for gastric adenocarcinoma patients in which part or all of the stomach is removed

Timeline

• Start date: 2025-01-16
• Primary completion: 2025-01-31
• Completion: 2025-01-31
• First posted: 2025-01-29
• Last updated: 2025-01-29

Locations

1 site across 1 country: China